文献速递糖尿病

基础胰岛素联合GLP-1受体激动剂治疗时血糖变异性与低血糖最低(VARIATION研究)

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).
PubMed 文献 · Diabetes Care · 2016-12-02

该队列研究用连续血糖监测(CGM)比较4种常见胰岛素方案治疗控制良好的2型糖尿病患者的血糖变异性(GV)。结果显示,基础胰岛素+GLP-1受体激动剂组的日间血糖标准差及CGM低血糖均最低,校正年龄、BMI、糖尿病病程和A1C后仍成立;作者认为这些获益可能有助于解释GLP-1受体激动剂治疗的心血管结局改善,需进一步研究。

要点

  • 基础胰岛素+GLP-1受体激动剂组日间血糖标准差显著低于基础胰岛素+口服药组、预混胰岛素组和基础-餐时胰岛素组。
  • CGM日间低血糖结局同样以基础胰岛素+GLP-1受体激动剂组最少。
  • 作者认为GV与低血糖获益可能有助于解释GLP-1受体激动剂治疗的心血管结局改善,需进一步研究。

核心结论

  • 使用基础胰岛素联合GLP-1受体激动剂的患者观察到最低的血糖变异性和最低的低血糖,支持这两类药物在2型糖尿病中的互补降糖作用。
  • 作者认为这些GV和低血糖方面的获益可能有助于解释GLP-1受体激动剂治疗所见到的心血管结局改善,并应进一步研究。

研究设计与样本

  • 研究为队列研究,来自三家内分泌门诊的连续患者,符合标准:2型糖尿病、年龄18至80岁、BMI≤45 kg/m2、稳定胰岛素方案至少6个月、入组前A1C稳定≤7.5%(58 mmol/mol),接受6天盲法CGM。
  • 共160例基线特征可比的患者形成四个等样本量的胰岛素方案队列:基础胰岛素+口服药(BO)、基础胰岛素+GLP-1受体激动剂(BGLP)、预混胰岛素(PM)、基础-餐时胰岛素(BB)。
  • 低血糖定义为CGM传感器葡萄糖浓度<70 mg/dL。

主要发现

  • 日间血糖标准差(主要结局)在BGLP队列显著低于BO、PM和BB队列(P=0.03、P=0.01和P<0.01),校正年龄、BMI、2型糖尿病病程和A1C后仍如此。
  • CGM日间低血糖结局同样以BGLP队列最少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a dearth of published literature comparing glucose variability (GV) between different insulin regimens in type 2 diabetes. This cohort study compares GV using continuous glucose monitoring (CGM) in patients with well-controlled type 2 diabetes using four common insulin regimens: basal insulin + oral drugs (BO), basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), premixed insulin (PM), and basal-bolus insulin (BB). RESEARCH DESIGN AND METHODS: Consecutive patients from three endocrinology clinics who met study criteria-type 2 diabetes, age 18 to 80 years, BMI ≤ 45 kg/m2, stable insulin regimen for a minimum of 6 months, and stable A1C value ≤7.5% (58 mmol/mol) before study enrollment-underwent 6-day masked CGM. Hypoglycemia was defined as a sensor glucose concentration <70 mg/dL on CGM. RESULTS: A total of 160 patients with comparable baseline characteristics formed four equal insulin regimen cohorts. The daily glucose SD (the primary outcome) was significantly lower in the BGLP cohort versus the BO, PM, and BB cohorts (P = 0.03, P = 0.01, and P < 0.01, respectively), and remained so after adjusting for age, BMI, type 2 diabetes duration, and A1C. Similarly, daily hypoglycemia outcomes on CGM were least for the BGLP cohort. CONCLUSIONS: The lowest GV and lowest hypoglycemia were observed in patients using the combination of basal insulin with a GLP-1 RA, supporting the complementary glycemic action of these agents in type 2 diabetes. These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bajaj HS, Venn K, Ye C, et al. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care. 2016. PMID: 27913575. doi:10.2337/dc16-1582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。